^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BTK C481

    i
    Other names: BTK, Bruton Tyrosine Kinase, Bruton Agammaglobulinemia Tyrosine Kinase, Tyrosine-Protein Kinase BTK, Bruton'S Tyrosine Kinase, B-Cell Progenitor Kinase, AGMX1, ATK, BPK, Tyrosine-Protein Kinase BTK Isoform (Lacking Exon 13 To 17), Dominant-Negative Kinase-Deficient Brutons Tyrosine Kinase, Tyrosine-Protein Kinase BTK Isoform (Lacking Exon 14), Truncated Bruton Agammaglobulinemia Tyrosine Kinase, Agammaglobulinaemia Tyrosine Kinase, Agammaglobulinemia Tyrosine Kinase, PSCTK1, IGHD3, IMD1, XLA, AT
    Entrez ID:
    695
    Related biomarkers:
    Expression
    Mutation
    Apply
    A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) (BELLWAVE-001) (NCT03162536)
    Phase 1/2
    ArQule, Inc., a subsidiary of Merck Sharp & Doh...
    Active, not recruiting
    Last update posted :
    03/08/2024
    Initiation :
    06/26/2017
    Primary completion :
    09/12/2025
    Completion :
    09/12/2025
    BCL2 • BCL6
    |
    BTK mutation • BCL6 translocation • BTK C481
    |
    nemtabrutinib (MK-1026)
    A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies (NX-2127-001) (NCT04830137)
    Phase 1
    Nurix Therapeutics, Inc.
    Active, not recruiting
    Last update posted :
    11/07/2023
    Initiation :
    05/05/2021
    Primary completion :
    12/01/2024
    Completion :
    12/01/2025
    TP53 • CD4
    |
    TP53 mutation • BTK C481
    |
    zelebrudomide (NX-2127)